Researcher Floribert Patrick Endong had been looking forward to seeing his paper in print. Several months after he submitted it to Gender Studies, the journal told him in March that it was online. But when he read it, Endong was disappointed to see some changes he had not approved, which he believed “deformed much of the initial text.”
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery,the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?
A journal has retracted a 2014 paper because of an authorship dispute that became the subject of litigation.
Last year, the Allegheny Health Network in Pittsburgh requested the paper be retracted to resolve the dispute. The Journal of Applied Biomaterials & Functional Materials retracted the paper in October.
According to the retraction notice, the principal investigator of a clinical trial on which some of the study is based was not included as a co-author, and claimed he had not “validated the accuracy of the data.”
The notice does not mention a lawsuit, but a letter from the authors’ research institution does.
But the study, especially its methodology, met with immediate criticism in the article’s comment section. PLOS ONEnoted in March 2016 that the authors had contacted the journal regarding an error in some of the exposure levels reported in the study, which journal staff were “looking into.” In December 2016, the journal told the authors it was going to retract the paper. Now, more than one year later, it finally has.
A journal retracted a paper about how conflicts of interest might be influencing research into the link between vaccines and autism because — wait for it — the authors failed to disclose conflicts of interest.
According to the retraction notice, the editors retracted the paper without the authors’ agreement, because the authors had a host of personal and professional interests in the field they didn’t declare, such as being associated with organizations involved in autism and vaccine safety. What’s more, the article also contained “a number of errors, and mistakes of various types that raise concerns about the validity of the conclusion.”
Carlo Croce, a cancer researcher who has faced numerous research misconduct allegations, recently accused a former lab member of misconduct. Although an institutional probe did not support that allegation, Croce’s efforts have led to a retraction.
In November 2015, Croce and another cancer researcher at Ohio State University (OSU), Ramiro Garzon, contacted PLOS ONE, alleging that the paper’s corresponding author, Stefan Costinean, published data without their knowledge or permission and without “accurately acknowledging their contributions to the research.” Although the PLOS ONE paper mentioned Croce’s and Garzon’s contributions in the acknowledgements section, the two were not included as co-authors. We have obtained a copy of the report describing OSU’s preliminary probe; it did not find evidence of misconduct, but recommended the paper be retracted for using data without permission. Although Costinean disagreed, the journal has since retracted the paper.
Here’s a head-scratcher: A 2017 paper examining why long space flights can cause eye damage has been taken down, with a brief note saying NASA, which sponsored the research, asked for the retraction because of “security concerns.”
According to the first author, the paper included information that could identify some of the astronauts that took part in the study — namely, their flight information. Although the author said he removed the identifying information after the paper was online, NASA still opted to retract it. But a spokesperson at NASA told us the agency did not supply the language for the retraction notice. The journal editor confirmed the paper was retracted for “research subject confidentiality issues,” but referred a question about who supplied the language of the notice back to NASA.
Now lawyers are involved.
So we still have some questions about this one. Here’s what we do know.
In July 2017, just days after accepting and publishing a paper, a physics journal discovered “several scientific errors” and decided to retract it.
But the authors—Alexander Kholmetskii and Tolga Yarman—strongly objected to the journal’s decision, so much so they published a detailed rebuttal to the retraction on the preprint server arXiv.
The paper explores a new principle related to Einstein’s theory of relativity. According to the authors, after the Canadian Journal of Physics notified them on July 17 about the decision to retract the paper, they asked the editor to publish their objection “to defend our sound point of view, and beyond this, our scientific reputation.” But Kholmetskii—who lists his affiliation at Belarus State University in Minsk, and Yarman, a professor at Okan University in Istanbul—told us that the editor found their response “inappropriate.” As a result, the authors turned to aiXiv to protest the retraction.
Journals are raising ethical concerns about the research of a doctor who offers controversial embryonic stem cell treatments.
Two journals have issued expressions of concern for three papers by Geeta Shroff, who was the subject of a 2012 CNN investigative documentary. All cite ethical concerns; one mentions the potential link between the procedure the authors describe and a risk of forming teratomas, a type of tumor. Shroff has objected to all three notices.
At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.
The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.